Guangzhou Wondfo Biotech Co.,Ltd

Equities

300482

CNE100002102

Medical Equipment, Supplies & Distribution

End-of-day quote Shenzhen S.E. Other stock markets 23:00:00 15/05/2024 BST			5-day change	1st Jan Change
28.76 ^CNY	-0.03%		-2.28%	-4.67%

05-06	Wondfo Biotech's Unit Gets Emergency Use Authorization from US FDA	MT
04-21	Guangzhou Wondfo Biotech Co.,Ltd Reports Earnings Results for the First Quarter Ended March 31, 2024	CI

Tranche Update on Guangzhou Wondfo Biotech Co.,Ltd's Equity Buyback Plan announced on September 26, 2022.

October 12, 2022 at 09:52 am

From September 26, 2022 to October 11, 2022, the company has repurchased 1,046,200 shares, representing 0.24% for CNY 30.1 million. With this, the company has completed the repurchase of 1,046,200 shares, representing 0.24% for CNY 30.1 million under the buyback announced on September 26, 2022.

Latest news about Guangzhou Wondfo Biotech Co.,Ltd

Wondfo Biotech's Unit Gets Emergency Use Authorization from US FDA	05-06	MT
Guangzhou Wondfo Biotech Co.,Ltd Reports Earnings Results for the First Quarter Ended March 31, 2024	04-21	CI
Guangzhou Wondfo Biotech Co.,Ltd Reports Earnings Results for the Nine Months Ended September 30, 2023	25/10/23	CI
Guangzhou Wondfo Biotech Co.,Ltd Reports Earnings Results for the Half Year Ended June 30, 2023	15/08/23	CI
Tranche Update on Guangzhou Wondfo Biotech Co.,Ltd's Equity Buyback Plan announced on July 5, 2023.	12/07/23	CI
Guangzhou Wondfo Biotech Co.,Ltd's Equity Buyback announced on July 5, 2023 has closed with 1,121,900 shares, representing 0.25% for CNY 30.1 million.	10/07/23	CI
Guangzhou Wondfo Biotech Co.,Ltd announces an Equity Buyback for CNY 50 million worth of its shares.	05/07/23	CI
Guangzhou Wondfo Biotech Co.,Ltd authorizes a Buyback Plan.	04/07/23	CI
Beijing PolySeq Technology Co., Ltd. announced that it has received CNY 100 million in funding from Guangzhou Wondfo Biotech Co.,Ltd, Guangzhou Sanmei Investment Management Center (Limited Partnership), Shangshi Capital, IDG Capital Partners Co., Ltd., Tsinghua Innovation Ventures	11/05/23	CI
Guangzhou Wondfo Biotech Co.,Ltd Reports Earnings Results for the First Quarter Ended March 31, 2023	25/04/23	CI
Guangzhou Wondfo Biotech Co.,Ltd Approves the Cash Dividend for the Year 2022, Payable on 18 May 2023	24/04/23	CI
Announcement on Resolutions of the 2022 Annual General Meeting of Guangzhou Wondfo Biotech	21/04/23	CI
Guangzhou Huiyin Tianyue Nominates Mr.Ge Xinhua as Supervisor	10/04/23	CI
Guangzhou Wondfo Biotech Co.,Ltd Proposes Final Cash Dividend for the Year 2022	31/03/23	CI
Guangzhou Wondfo Biotech Co.,Ltd Reports Earnings Results for the Full Year Ended December 31, 2022	30/03/23	CI
Beijing PolySeq Technology Co., Ltd. announced that it expects to receive CNY 40 million in funding from Guangzhou Wondfo Biotech Co.,Ltd, Guangzhou Sanmei Investment Management Center (Limited Partnership), Shangshi Capital, IDG Capital Partners Co., Ltd., Tsinghua Innovation Ventures	19/03/23	CI
Investors bet on greed and fear as China loosens COVID grip	09/12/22	RE
Guangzhou Wondfo Biotech Co.,Ltd Reports Earnings Results for the Nine Months Ended September 30, 2022	27/10/22	CI
Tranche Update on Guangzhou Wondfo Biotech Co.,Ltd's Equity Buyback Plan announced on September 26, 2022.	12/10/22	CI
Guangzhou Wondfo Biotech Co.,Ltd's Equity Buyback announced on September 26, 2022, has expired with 1,046,200 shares, representing 0.24% for CNY 30.10 million.	10/10/22	CI
Guangzhou Wondfo Biotech Co.,Ltd announces an Equity Buyback for CNY 50 million worth of its shares.	26/09/22	CI
Guangzhou Wondfo Biotech Co.,Ltd authorizes a Buyback Plan.	25/09/22	CI
Guangzhou Wondfo Biotech Co.,Ltd Reports Earnings Results for the Half Year Ended June 30, 2022	25/08/22	CI
Guangzhou Wondfo Biotech Co.,Ltd announced that it expects to receive CNY 1 billion in funding	18/08/22	CI
Guangzhou Wondfo Biotech Co.,Ltd Announces Cash Dividend, Payable on 14 June 2022	08/06/22	CI

Chart Guangzhou Wondfo Biotech Co.,Ltd

Duration

Period

More charts

Company Profile

GUANGZHOU WONDFO BIOTECH CO., LTD. is a China-based company principally engaged in research, manufacture and sales of point-of-care testing (POCT) reagents, POCT instrument and related products. According to the testing result, the Company' products can be divided into qualitative testing products and quantitative testing products. According to the usage, the Company' products include pregnancy testing series, infectious diseases testing series, drugs (drug abuse) testing series and chronic disease testing series. The Company's products are used in POCT, clinical test, field test and personal health management, among others.

Sector

Medical Equipment, Supplies & Distribution

Calendar

28/08/2024 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Ratings for Guangzhou Wondfo Biotech Co.,Ltd

Trading Rating

Investor Rating

ESG Refinitiv

D+

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

28.76 CNY

Average target price

35.24 CNY

Spread / Average Target

+22.54%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Diagnostic & Testing Substances

	1st Jan change	Capi.
GUANGZHOU WONDFO BIOTECH CO.,LTD	-4.67%	1.87B
BIOMÉRIEUX	-4.32%	12.33B
SHENZHEN NEW INDUSTRIES BIOMEDICAL ENGINEERING CO., LTD.	-4.35%	8.14B
DIASORIN S.P.A.	+9.07%	5.89B
LANTHEUS HOLDINGS, INC.	+30.81%	5.62B
AUTOBIO DIAGNOSTICS CO., LTD.	-7.42%	4.24B
10X GENOMICS, INC.	-54.27%	3.06B
ANDON HEALTH CO., LTD.	+14.44%	2.76B
VITROLIFE AB	-1.13%	2.41B
MYRIAD GENETICS, INC.	+28.53%	2.23B

Diagnostic & Testing Substances